First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228).
Francis Levi
No relevant relationships to disclose
Michel Ducreux
No relevant relationships to disclose
Mohamed Hebbar
No relevant relationships to disclose
Philippe Rougier
No relevant relationships to disclose
C. N. J. Focan
No relevant relationships to disclose
Rosine Guimbaud
No relevant relationships to disclose
Carlos Carvalho
No relevant relationships to disclose
Salvatore Tumolo
No relevant relationships to disclose
Pasquale F. Innominato
No relevant relationships to disclose
Yves Ajavon
No relevant relationships to disclose
Denis Castaing
No relevant relationships to disclose
Thierry De Baere
No relevant relationships to disclose
Abdoulaye Karaboué
No relevant relationships to disclose
Celine Lepere
No relevant relationships to disclose
Valerie Boige
No relevant relationships to disclose
Laetitia Proux
No relevant relationships to disclose
Rene Adam
No relevant relationships to disclose
Mohamed Bouchahda
No relevant relationships to disclose